Sharon Winton, the CEO and director of Lymphoma Australia, said, “Patients living with DLBCL deserve options at every stage of their treatment journey. The availability of another treatment option for patients who have already undergone two or more lines of therapy acknowledges this need and is welcomed by the community.”
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News